The system provides an estimate of in vivo efficacy of commonly used antiretroviral drug combinations based on user-defined information of HIV genotype (mandatory) and additional patient information (recommended). The engine is not intended as a replacement for standard of care but can be used by HIV specialists as an additional treatment decision support tool. Although analysis of a large data set of medical records has shown a good performance of the system, there is no warranty that its use will improve patient health. HIV care must rely on a solid knowledge of the complex host-virus interaction and proper consideration of patient status and commitment.


The EuResist Integrated DataBase (EIDB) was set up to develop the EuResist prediction system. The EIDB is currently one of the largest data sets suitable for training genotype-centered treatment response models.

The EIDB is open for scientific studies under approval of the Scientific Board and following the Authorship Policy.

The EIDB includes information about patients, drug therapies, AIDS defining events, CD4 and viral load measurements and HIV genomic sequences. As of October 2019 it contains the following data:

# patients 103.475
# therapies (not single drugs but CARTs) 231.934
# viral load measurements 1.389.577
# cd4 measurements 1.410.255
# sequences (TOT) 119.937
# PR+RT sequences 79.687
# INT sequences 12.541
# gag sequences  
# env sequences (env, V3, GP41, GP120) 7.573
# therapies with rilpivirine 7.535
# therapies with dolutegravir 13.884
# therapies with elvitegravir 4.409
# therapies with darunavir 20.371
# therapies with maraviroc 2.396
# therapies with raltegravir 10.983
# therapies with etravirine 439

The EIDB integrates biomedical information from the three founding national databases: the ARCA database (Italy), the AREVIR database (Germany), and data from Karolinska Institute (Sweden). The original data set is continuously updated with new data in order to improve the accuracy of the prediction system.

Following the EIDB setup, other centers’ data have also been uploaded:

Instituto de Higiene e Medicina Tropical (Portugal); irsiCaixa Foundation (Spain); the Rega Institute (Belgium); Laboratoire de Rétrovirologie of CRP-Santé (Luxembourg), data from the DUET study conducted by Tibotec, Boheringer Ingelheim study, the National Referral Laboratory of Rwanda, Ivanovsky Institute of virology (Russia), Koacaeli University Medical Faculty (Turkey), CoRIS cohort (Spain).

As of 2019, the following centres provide continuously updated data to the EIDB:

ARCA Italy
AREVIR Germany
Karolinska Institute Sweden
Instituto de Higiene e Medicina Tropical Portugal
irsiCaixa Foundation Spain
Laboratoire de Rétrovirologie of CRP-Santé Luxembourg
Ivanovsky Institute of virology Russia
Koacaeli University Medical Faculty Turkey
CoRIS cohort Spain

How to contribute to the data base

You can contribute your data to the EuResist initiative and have the possibility to query the whole data set for study proposals (upon request). In order to facilitate the entry of additional data providers, general rules for participation have been agreed upon as follows.

  1. Data provided by external contributors are provided solely for development of the treatment response models (i.e. the focus of the EuResist project); any other use is subject to information to and explicit approval by the contributing center;
  2. The task of integrating new data into the EIDB will be carried out by EuResist with the collaboration of the data provider, limited to providing information on database platform and schema and sending data via the method agreed upon. Integrating data ensures a quality control made by the EIDB administrator at the advantage of the contributing center;
  3. The co-authorship policy reserves one slot for each data provider in each scientific paper and congress presentation provided this is in-line with the journal editorial policy in terms of limitation in the number of authors or kind of work performed;
  4. Data contributed remain the property of the contributing center for ever. The data provider reserves the right to have its data permanently removed from EIDB at any moment without any need to justify this decision. Should this occur, the data are considered available only for pending papers explicitly agreed upon, i.e. being submitted for publication;
  5. Should EuResist end, each external dataset will be removed from the EIDB unless the contributing center explicitly requests that the data remain in the EIDB